Clinical Trials on Severe Hepatic Impairment

Total 9814 results

Pfizer

Recruiting

A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction

Healthy Volunteers | Moderate Hepatic Impairment | Severe Hepatic Impairment

United States
EQRx International, Inc.

Completed

An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143

Severe Hepatic Impairment

United States
Pfizer

Completed

Evaluate Severe Hepatic Impairment on Dacomitinib PK

Severe Hepatic Impairment

United States
Takeda

Completed

Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment

Severe Hepatic Impairment

United States
Bausch Health Americas, Inc.

Terminated

Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects

Severe Hepatic Impairment

United States
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men

Severe Hepatic Impairment | Normal Hepatic Function

Bulgaria
Mitsubishi Tanabe Pharma Corporation

Completed

PK Study in Subjects With Severe Hepatic Impairment (MCI-186-E05 HP)

Healthy | Severe Hepatic Impairment

Czechia, Hungary, Slovakia
Genfit

Completed

Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

Liver Diseases | Moderate Hepatic Impairment | Severe Hepatic Impairment

United States
H. Lundbeck A/S

Completed

Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects

Heptic Impairment

Germany
GlycoMimetics Incorporated

Completed

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Moderate Hepatic Impairment | Normal Hepatic Function

United States
Agios Pharmaceuticals, Inc.

Completed

A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function

Moderate Hepatic Impairment

United States
Merck Sharp & Dohme LLC

Completed

Belzutifan (MK-6482) Hepatic Impairment Study (MK-6482-020)

Moderate Hepatic Impairment

United States
KBP Biosciences
Covance

Completed

Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment

Healthy | Moderate Hepatic Impairment

United States
Tibotec BVBA

Completed

A Study of TMC207 in Patients With Moderately Impaired Hepatic Function

Moderate Hepatic Impairment
Shire

Completed

Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants

Hepatic Impairment

United States
Sunshine Lake Pharma Co., Ltd.

Completed

To Evaluate the Pharmacokinetics and Safety of Yimitasvir Phosphate Capsules in Subjects With Moderate and Severe Liver Function Impairment and in Healthy Subjects

Hepatic Impairment

China
Janssen Research & Development, LLC

Withdrawn

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function

Hepatic Impairment
Jazz Pharmaceuticals

Completed

Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients

Hepatic Impairment

United States
Seagen Inc.

Completed

A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects

Hepatic Impairment

United States
Taisho Pharmaceutical Co., Ltd.

Completed

A Pharmacokinetic Study of TS-142 in Patients With Hepatic Impairment

Patients With Mild or Moderate Hepatic Impairment

Japan
Eli Lilly and Company
Loxo Oncology, Inc.

Completed

A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants

Healthy | Hepatic Impairment

United States
Astellas Pharma Europe B.V.

Completed

A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects

Healthy Subjects | Pharmacokinetics | Mild and Moderate Hepatic Impairment

Slovakia
Daiichi Sankyo, Inc.

Completed

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

Moderate Hepatic Impairment

United States
Atea Pharmaceuticals, Inc.

Recruiting

Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment | Healthy Volunteer

United States
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants

Hepatic Impairment | Healthy Participants

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver Function

Healthy Subjects | Hepatic Impairment

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

An Investigational Study of SHR6390 in Participants With Mild to Moderate Liver Impairment and Healthy Participants

Hepatic Impairment | Healthy Participants
Merck Sharp & Dohme LLC

Completed

A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)

Chronic Hepatic Impairment
Nektar Therapeutics

Completed

A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)

Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

Mild and Moderate Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Effect of Hepatic Impairment on LDK378 Pharmacokinetics

Normal Hepatic Function | Impaired Hepatic Function

United States
Eisai Inc.

Completed

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

Hepatic Impairment | Hepatic Function

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine

Hepatic Impairment | Normal Hepatic Function

United States
Theodor Bilharz Research Institute
Cairo University

Completed

PVB Versus TAP in Hepatic Patients Undergoing Laparoscopic Cholecystectomy

Hepatic Impairment | Laparoscopic Cholecystectomy | Ultrasound Therapy

Egypt
Biotie Therapies Inc.
Acorda Therapeutics

Terminated

Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

Hepatic Impairment

United States
Daiichi Sankyo, Inc.

Completed

A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment

Hepatic Impairment | Moderate Impaired Hepatic Function

United States
Acerta Pharma BV
AstraZeneca

Completed

Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite

Hepatic Insufficiency | Healthy Subjects | Hepatic Impairment

United States
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine

Hepatic Impairment

United States
AstraZeneca

Recruiting

Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment

Hepatic Impairment

United States
Novo Nordisk A/S

Recruiting

A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Behaves in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function

Hepatic Impairment

Germany, Slovakia
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)

Hepatic Impairment

United States
Kyowa Kirin, Inc.

Completed

Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite

Hepatic Impairment

United States
Amgen

Completed

Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment

Hepatic Impairment

United States
Basilea Pharmaceutica

Active, not recruiting

A Clinical Trial of the Study Medicine (Called Fosmanogepix) in People With Hepatic Dysfunction.

Hepatic Impairment

United States
AstraZeneca

Completed

Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

Hepatic Impairment

United States, Bulgaria, Slovakia
Bristol-Myers Squibb

Completed

A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment

Hepatic Impairment

United States
Guangdong Raynovent Biotech Co., Ltd

Completed

Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Hepatic Impairment

Hepatic Impairment

China
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Influence of Hepatic Impairment on MK-8189 Treatment (MK-8189-012)

Hepatic Impairment

United States
Amgen

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics Study of FIA586 in Participants With Mild and Moderate Hepatic Impairment

Hepatic Impairment

United States

3

Subscribe